Epoprostenol treatment for idiopathic pulmonary arterial hypertension in pregnancy

Journal of Perinatology

Volumn 30, Issue 9, 2010, Pages 628-631

  Garabedian, M J ^a   Hansen, W F ^a   Gianferrari, E A ^a   Lain, K Y ^a   Fragneto, R Y ^a   Campbell, C L ^b   Booth, D C ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BETAMETHASONE; ENOXAPARIN; INDOMETACIN; LUNG SURFACTANT; NIFEDIPINE; NITRIC OXIDE; PHENYLEPHRINE; PROSTACYCLIN; SILDENAFIL;

ADULT; ANESTHESIA INDUCTION; ARTICLE; CASE REPORT; CESAREAN SECTION; CHILDBIRTH; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG DOSE TITRATION; DYSPNEA; ECLAMPSIA; FEMALE; HEART OUTPUT; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPOTENSION; IDIOPATHIC DISEASE; INTENSIVE CARE UNIT; LUNG ARTERY PRESSURE; LUNG FUNCTION TEST; MATERNAL HYPERTENSION; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN; PATENT DUCTUS ARTERIOSUS; PATIENT CARE PLANNING; PLACENTAL DELIVERY; PULMONARY HYPERTENSION; SIDE EFFECT;

ADULT; ANTIHYPERTENSIVE AGENTS; CESAREAN SECTION, REPEAT; EPOPROSTENOL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; PATIENT CARE TEAM; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR;

EID: 77956250397     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/jp.2010.15     Document Type: Article

References (25)

1. Bonnin M, Mercier FJ, Sitbon O, Roger-Christoph S, Jais X, Humbert M et al. Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases. Anesthesiology 2005; 102(6): 1133-1137; discussion 5A-6A.
2. Smedstad KG, Cramb R, Morison DH. Pulmonary hypertension and pregnancy: a series of eight cases. Can J Anaesth 1994; 41(6): 502-512.
3. Weiss BM, Zemp L, Seifert B, Hess OM. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J Am Coll Cardiol 1998; 31(7): 1650-1657.
4. Stewart R, Tuazon D, Olson G, Duarte AG. Pregnancy and primary pulmonary hypertension: successful outcome with epoprostenol therapy. Chest 2001; 119(3): 973-975.
5. Huang S, DeSantis ER. Treatment of pulmonary arterial hypertension in pregnancy. Am J Health Syst Pharm 2007; 64(18): 1922-1926.
6. Robinson JN, Banerjee R, Landzberg MJ, Thiet MP. Inhaled nitric oxide therapy in pregnancy complicated by pulmonary hypertension. Am J Obstet Gynecol 1999; 180(4): 1045-1046.
7. Macchia A, Marchioli R, Marfisi R, Scarano M, Levantesi G, Tavazzi L et al. A metaanalysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J 2007; 153(6): 1037-1047.
8. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334(5): 296-302.
9. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40(4): 780-788.
10. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation 2006; 114(13): 1417-1431.
11. Robson SC, Hunter S, Boys RJ, Dunlop W. Serial study of factors influencing changes in cardiac output during human pregnancy. Am J Physiol 1989; 256(4 Pt 2): H1060-H1065.
12. Clark SL, Cotton DB, Lee W, Bishop C, Hill T, Southwick J et al. Central hemodynamic assessment of normal term pregnancy. Am J Obstet Gynecol 1989; 161(6 Pt 1): 1439-1442.
13. Church AC, Sanabria D, Peacock A, Johnson M. Epoprostenol use in a National Pulmonary Hypertension Centre from 1997 to 2007. Thorax 2009; 64(7): 642.
14. Jacobs W, Boonstra A, Marcus JT, Postmus PE, Vonk-Noordegraaf A. Addition of prostanoids in pulmonary hypertension deteriorating on oral therapy. J Heart Lung Transplant 2009; 28(3): 280-284.
15. Bedard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? Eur Heart J 2009; 30(3): 256-265.
16. Spence S, Anderson C, Cukierski M, Patrick D. Teratogenic effects of the endothelin receptor antagonist L-753,037 in the rat. Reprod Toxicol 1999; 13(1): 15-29.
17. Easterling TR, Ralph DD, Schmucker BC. Pulmonary hypertension in pregnancy: treatment with pulmonary vasodilators. Obstet Gynecol 1999; 93(4): 494-498.
18. Monnery L, Nanson J, Charlton G. Primary pulmonary hypertension in pregnancy; a role for novel vasodilators. Br J Anaesth 2001; 87(2): 295-298.
19. Jacobs W, Vonk-Noordegraaf A. Epoprostenol in pulmonary arterial hypertension. Expert Opin Drug Metab Toxicol 2009; 5(1): 83-90.
20. Garin MC, Clark L, Chumney EC, Simpson KN, Highland KB. Cost-utility of treatments for pulmonary arterial hypertension: a Markov state-transition decision analysis model. Clin Drug Investig 2009; 29(10): 635-646.
21. Nahapetian A, Oudiz RJ. Serial hemodynamics and complications of pregnancy in severe pulmonary arterial hypertension. Cardiol Karger AG 2008; 109(4): 237-240.
22. OHare R, McLoughlin C, Milligan K, McNamee D, Sidhu H. Anaesthesia for caesarean section in the presence of severe primary pulmonary hypertension. Br J Anaesth 1998; 81(5): 790-792.
23. Paternoster DM, Pascoli I, Parotto M, Cester M, Nanhorngue K, Merati E et al. Pulmonary hypertension during pregnancy: management of two cases. Arch Gynecol Obstet 2010; 281(3): 431-434.
24. Wong PSC, Constantinides S, Kanellopoulos V, Kennedy CR, Watson D, Shiu MF. Primary pulmonary hypertension in pregnancy. J R Soc Med 2001; 94(10): 523-525.
25. Coceani F, Bodach E, White E, Bishai I, Olley PM. Prostaglandin I2 is less relaxant than prostaglandin E2 on the lamb ductus arteriosus. Prostaglandins 1978; 15(4): 551-556.